The European Pharmacopoeia is published by the European Directorate for the Quality of Medicines & HealthCare (EDQM) of the Council of Europe in Strasbourg. The publication contains standardised specifications defining the quality of pharmaceutical preparations, their constituents and containers.
The Finnish Medicines Agency Fimea is the Finnish national authority in pharmacopoeia matters.
The European Pharmacopoeia can be ordered from:
- EDQM Online Store
- EDQM Publications, (European Pharmacopoeia), 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; fax +33 3 88 41 27 71; e-mail: email@example.com
The fourth supplement of the tenth edition of the European Pharmacopoeia (European Pharmacopoeia 10th Edition, Supplement 10.4) has been implemented on April 1st, 2021.
The five monographs on sartans, namely Valsartan (2423), Losartan potassium (2232), Irbesartan (2465), Candesartan cilexetil (2573) and Olmesartan medoxomil (2600), have been revised to align them with the latest regulatory recommendations issued by the CHMP regarding N-nitrosamines. The monographs have been published under the rapid-revision procedure and their implementation date has been set at 1 April 2021. Please read more on EDQM website.
The National pharmacopoeia documents have been updated according to the fourth supplement of the tenth edition.